Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Interaction of Nevirapine, Abacavir, and Amprenavir in HIV-1
NCT02182765Phase 1Terminated
- Sponsor
- Boehringer Ingelheim
- Start
- Apr 1999
- Primary completion
- Jul 2001
- Modality
- Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of nevirapine in human immunodeficiency virus type 1 infection (HIV-1), sponsored by Boehringer Ingelheim. Primary endpoints: Area Under Plasma Concentration Time Curve of Amprenavir at Day 43, Maximum Observed Concentration of Amprenavir at Day 43 and 2 more. Started Apr 1999; status: terminated.
02
Drugs
nevirapine
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT02182765.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02182765.